Levofenfluramine: Difference between revisions
CSV import |
CSV import |
||
| Line 26: | Line 26: | ||
{{stub}} | {{stub}} | ||
{{No image}} | {{No image}} | ||
== Levofenfluramine == | |||
<gallery> | |||
File:levofenfluramine.svg|Levofenfluramine | |||
File:Fenfluramine,levo 3D BS.png|Levofenfluramine 3D Structure | |||
</gallery> | |||
Revision as of 01:45, 20 February 2025
Levofenfluramine is a drug that was previously used as an appetite suppressant, but was withdrawn from the market due to its potential to cause pulmonary hypertension and heart valve disease. It is the levorotatory enantiomer of the amphetamine derivative fenfluramine.
History
Levofenfluramine was first synthesized in the 1970s and was marketed as an appetite suppressant. However, it was withdrawn from the market in the late 1990s due to concerns about its potential to cause pulmonary hypertension and heart valve disease.
Pharmacology
Levofenfluramine acts as a serotonin releasing agent. It increases the concentration of serotonin in the brain, which leads to a decrease in appetite. However, it also has the potential to cause pulmonary hypertension and heart valve disease.
Side Effects
The most common side effects of levofenfluramine include dizziness, dry mouth, insomnia, and constipation. However, the most serious side effects are pulmonary hypertension and heart valve disease.
Withdrawal from the Market
Levofenfluramine was withdrawn from the market in the late 1990s due to concerns about its potential to cause pulmonary hypertension and heart valve disease. This decision was based on several studies that showed a significant increase in the risk of these conditions in people who used the drug.
